Discovery of new inhibitors of nuclease MRE11

Investor logo
Investor logo

Warning

This publication doesn't include Institute of Computer Science. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

NIKULENKOV Fedor CARBAIN Benoit Jean-Pierre BISWAS Raktim HAVEL Štěpán PROCHÁZKOVÁ Jana SISÁKOVÁ Alexandra ZACPALOVÁ Magdaléna CHAVDAROVA Melita MARINI PALOMEQUE María Victoria VŠIANSKÝ Vít WEISOVÁ Veronika SLÁVIKOVÁ Kristína BIRADAR Dhanraj Omprakash KHIRSARIYA PrashantKumar VITEK Marco SEDLAK David BARTUNEK Petr DANIEL Lukáš BREZOVSKÝ Jan DAMBORSKÝ Jiří PARUCH Kamil KREJČÍ Lumír

Year of publication 2025
Type Article in Periodical
Magazine / Source European Journal of Medicinal Chemistry
MU Faculty or unit

Faculty of Science

Citation
web https://doi.org/10.1016/j.ejmech.2024.117226
Doi http://dx.doi.org/10.1016/j.ejmech.2024.117226
Keywords MRE11 inhibitor; BRCA2; FEN1; nuclease
Description MRE11 nuclease is a central player in signaling and processing DNA damage, and in resolving stalled replication forks. Here, we describe the identification and characterization of new MRE11 inhibitors MU147 and MU1409. Both compounds inhibit MRE11 nuclease more specifically and effectively than the relatively weak state-of-theart inhibitor mirin. They also abrogate double-strand break repair mechanisms that rely on MRE11 nuclease activity, without impairing ATM activation. Inhibition of MRE11 also impairs nascent strand degradation of stalled replication forks and selectively affects BRCA2-deficient cells. Herein, we illustrate that our newly discovered compounds MU147 and MU1409 can be used as chemical probes to further explore the biological role of MRE11 and support the potential clinical relevance of pharmacological inhibition of this nuclease.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info